This correlation supports the study by Li et al., who showed that blocking CCL2/CCR2 signaling through CCR2 knockout or the use of a CCR2 antagonist effectively suppressed malignant development and metastasis of HCC, decreased the likelihood of recurrence after surgery, and improved overall survival [54], which is consistent with our MR results. The gene discussed is CCL2; the disease is hepatocellular carcinoma.